The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Kura Oncology, Inc. | COM | 50127T109 | 4,713,409 | 816,882 | SH | SOLE | 816,882 | 0 | 0 | ||
| Lyell Immunopharma, Inc. | COM | 55083R203 | 7,075,527 | 800,399 | SH | SOLE | 800,399 | 0 | 0 | ||
| Maze Therapeutics Inc | COM | 578784100 | 25,913,246 | 2,111,919 | SH | SOLE | 2,111,919 | 0 | 0 | ||
| Pharvaris N.V. | COM | N69605108 | 77,626,226 | 4,410,581 | SH | SOLE | 4,410,581 | 0 | 0 | ||
| Relay Therapeutics Inc. | COM | 75943R102 | 3,460,000 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
| Xenon Pharmaceuticals Inc | COM | 98420N105 | 5,008,000 | 160,000 | SH | SOLE | 160,000 | 0 | 0 | ||